MétaCan
Menu
Back to cohort
Record W4415296717 · doi:10.26685/urncst.894

Metformin and Mitochondrial Apoptosis in Breast Cancer: Mechanistic Insights and Therapeutic Implications

2025· article· W4415296717 on OpenAlexaff
Sanika Chitre, Helen J. Huang, Yilin Xu

Bibliographic record

VenueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2025
Typearticle
Language
FieldBiochemistry, Genetics and Molecular Biology
TopicMetabolism, Diabetes, and Cancer
Canadian institutionsMcMaster University
Fundersnot available
KeywordsMetforminAMPKApoptosisBreast cancerMitochondrionCarcinogenesisCancerMitochondrial ROS

Abstract

fetched live from OpenAlex

Metformin, a first-line treatment for type 2 diabetes, has gained potential for its anti-cancer properties. Evidence suggests that metformin suppresses tumour growth and induces apoptosis, particularly through its effects on mitochondrial pathways. This review explores three interconnected mechanisms by which metformin promotes mitochondrial-induced apoptosis and inhibits tumorigenesis in breast cancer: AMPK activation, reduced Bcl-2 protein activity, and ROS accumulation. These processes contribute to apoptotic reactivation mechanisms such as mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and cell death, offering insight into how metformin may help overcome treatment resistance in hormone receptor-positive and triple-negative breast cancers. Breast cancer was selected for this study due to its high global incidence and marked variability in treatment response, making it an ideal framework to evaluate metformin’s effects across different breast cancer subtypes. A systematic review was conducted to review metformin’s role in inducing apoptosis, focusing on its effects on mitochondrial processes related to AMPK activation, reduced Bcl-2 protein activity, and ROS production. The review draws research from databases such as PubMed, ScienceDirect, and the National Institutes of Health, using keywords such as metformin, mitochondrial apoptosis, tumorigenesis, and anticancer pathways. Studies were selected based on relevance to AMPK signaling, Bcl-2 modulation, and ROS involvement, with emphasis on apoptosis markers, breast cancer subtypes, and metformin dosage-response outcomes. Metformin’s role to activate AMPK, reduce Bcl-2 protein activity , and increase ROS collectively promote BAX/BAK oligomerization, mitochondrial outer membrane permeabilization (MOMP, and both caspase-dependent and caspase-independent apoptosis). These effects are expected to vary across breast cancer subtypes based on p53 status, ER expression, and metabolic profile. This review highlights metformin's potential as an anti-cancer agent by targeting various mitochondrial mechanisms, each contributing to apoptosis and inhibiting tumorigenesis. The findings can guide clinicians in integrating metformin into targeted cancer treatments to overcome cancer resistance. This research can support the development of metformin-based therapies that selectively target cancer cell vulnerabilities and guide future efforts in personalizing treatment based on tumour metabolism and genetic context.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.002
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.394
Teacher spread0.363 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) JournalSame topicMetabolism, Diabetes, and CancerFrench-language works237,207